The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?

2.

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

3.

More evidence links physical activity with improved cancer survival

4.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

5.

Xerostomia in Head and Neck Cancer Patients Can Be Predicted by Mid-Treatment PET/CT Scans.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot